Clinical Trial

BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease

Study acronym: BOOST-PD
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias. The change in the duration and quality of on-time will be measured by a wearable device placed on your wrist called KinesiaU.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-21.
Trial Details
NCT Number NCT07138560
Lead Sponsor The Cleveland Clinic
Collaborators: Amneal Pharmaceuticals, LLC
Conditions Parkinson Disease
Enrollment 22 participants
Start Date 2025-07-24
Primary Completion 2026-12-15 (estimated)
Study Completion 2027-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-23